Biocon Chief Extols Moderna’s Success To Spur ‘Risk-Averse’ VCs in India
Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.
You may also be interested in...
Industry leaders and experts, including executives from McKinsey, Eight Roads Ventures and Novartis, share global best practices, insights and expectations around how India could accelerate its journey towards becoming a biopharma innovation hub.
The Flagship Pioneering-founded start-up will build a “Gigabase Factory” to go from idea to in vivo proof of concept within eight weeks by rapidly manufacturing and running preclinical tests for multiple constructs at once.
The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.